Home/Pipeline/CARVYKTI® (ciltacabtagene autoleucel)

CARVYKTI® (ciltacabtagene autoleucel)

Multiple Myeloma

Phase 3Active

Key Facts

Indication
Multiple Myeloma
Phase
Phase 3
Status
Active
Company

About johnson-and-johnson

Johnson & Johnson is a diversified healthcare leader with a mission to prevent, treat, and cure complex diseases through smarter, less invasive, and more personalized solutions. Its strategic pivot to a pure-play Innovative Medicine and MedTech structure enhances focus and capital allocation towards high-margin, innovative therapies and advanced technologies. The company sustains its leadership through a formidable R&D engine, a robust commercial portfolio featuring multiple blockbuster drugs, and a disciplined strategy of strategic business development and portfolio optimization.

View full company profile